Antonio C. Bossi, MD

Articles by Antonio C. Bossi, MD

Potential Gender Differences of Exenatide in Outpatients With Type 2 Diabetes Mellitus

ByAntonio C. Bossi, MD,Anna Pulcina, MD,Eunice O. Ansah, MD,Annalisa Balini, MD,Denise Berzi, MD,Giancarla Meregalli, MD,Giovanni Veronesi, PhD

September 24th 2015

In outpatients with type 2 diabetes mellitus, persistent exenatide treatment lowered glycated hemoglobin and hyperglycemia in both genders. Waist circumference and body weight were more reduced in women.

Latest Updated Articles

Potential Gender Differences of Exenatide in Outpatients With Type 2 Diabetes Mellitus
Published: September 24th 2015 | Updated:

Antonio C. Bossi, MD

Articles by Antonio C. Bossi, MD

Potential Gender Differences of Exenatide in Outpatients With Type 2 Diabetes Mellitus

Latest Updated Articles

Trending on Pharmacy Times

Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma

States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments

FDA Expands Approval of Sotatercept-Csrk for Pulmonary Arterial Hypertension

Expert Insights on Key Data from IMS 2025

Study Shows Growing Confidence in Cell and Gene Therapies Across the Care Continuum